Simultaneous determination of parecoxib and its main metabolites valdecoxib and hydroxylated valdecoxib in mouse plasma with a sensitive LC-MS/MS method to elucidate the decreased drug metabolism of tumor bearing mice

被引:9
作者
Jin, Xiaoliang [1 ]
Zhou, Fang [1 ]
Liu, Yan [1 ]
Cheng, Chen [1 ]
Yao, Lan [1 ]
Jia, Yuanwei [1 ]
Wang, Guangji [1 ]
Zhang, Jingwei [1 ]
机构
[1] China Pharmaceut Univ, State Key Lab Nat Med, Key Lab Drug Metab & Pharmacokinet, Nanjing, Jiangsu, Peoples R China
关键词
Parecoxib; Valdecoxib; Hydroxylated valdecoxib; LC-MS/MS; Tumor bearing mice; RANDOMIZED CONTROLLED-TRIAL; SOLID-PHASE EXTRACTION; CANCER PAIN; ANTIINFLAMMATORY DRUGS; LIQUID-CHROMATOGRAPHY; COX-2; INHIBITOR; CELECOXIB; PHARMACOKINETICS; OSTEOARTHRITIS; PHARMACOLOGY;
D O I
10.1016/j.jpba.2018.05.034
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Parecoxib (PX), a prodrug of valdecoxib (VX), is an injectable selective COX-2 inhibitor, and is recommended for the treatment of cancer pain. PX can be rapidly hydrolyzed into its active metabolite VX, and VX is further metabolized into hydroxylated valdecoxib (OH-VX) by cytochrome P450 enzymes. However, cancer patients have been reported to possess reduced drug metabolism ability, which might cause excessive drug accumulation Such overdose of PX significantly increased the risk of renal safety and cardiovascular events. Therefore, it is necessary to elucidate the concentration profiles of PX and its metabolites in cancer status. In this study, a sensitive, rapid and specific LC-MS/MS method for quantification of PX, VX and OH-VX in the plasma of tumor bearing mouse was developed and validated. After protein precipitation, all the analytes were separated on an Agilent ZORBAX Extend-C18 HPLC column (2.1 x 100 mm, 3.5 mu m)with gradient elution. The analytes were detected by an electrospray negative ionization mass spectrometry in the multiple reaction monitoring mode. The transition m/z 369.0/ar=r/ 119.0,m/z 312.9/ar=r/ 117.9, m/z 329.0/ar=r/ 196.0, and m/z 307.1/ar=r/ 161.3 were used for monitoring PX, VX, OH-VX and IS respectively. The calibration curves of the analytes showed good linearity over the concentration range of3-3000 ng/mL for PX and VX, and 3-1000 ng/mL for OH-VX. Intra- and inter-batch accuracies (in terms of relative error, RE <9.9%) and precisions (in terms of relative standard deviation, RSD < 8.8%) satisfied the standard of validation. The matrix effect, recovery and stability were also within acceptable criteria. The method was successfully applied to the pharmacokinetics study of PX in tumor bearing mice, and PX and VX levels were found elevated with the growth of tumor volume, which might increase the risk of drug overdose. (C) 2018 Elsevier B.V. All rights reserved.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 37 条
[1]   Valdecoxib: the rise and fall of a COX-2 inhibitor [J].
Atukorala, Inoshi ;
Hunter, David J. .
EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (08) :1077-1086
[2]   Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial [J].
Bensen, WG ;
Fiechtner, JJ ;
McMillen, JI ;
Zhao, WW ;
Yu, SS ;
Woods, EM ;
Hubbard, RC ;
Isakson, PC ;
Verburg, KM ;
Geis, GS .
MAYO CLINIC PROCEEDINGS, 1999, 74 (11) :1095-1105
[3]   Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection [J].
Bushman, Lane R. ;
Kiser, Jennifer J. ;
Rower, Joseph E. ;
Klein, Brandon ;
Zheng, Jia-Hua ;
Ray, Michelle L. ;
Anderson, Peter L. .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2011, 56 (02) :390-401
[4]   Cardiovascular effects of valdecoxib: transducing human pharmacology results into clinical read-outs [J].
Capone, Marta L. ;
Tacconelli, Stefania ;
Di Francesco, Luigia ;
Petrelli, Maria ;
Patrignani, Paola .
EXPERT OPINION ON DRUG SAFETY, 2008, 7 (01) :29-42
[5]  
Capone ML, 2003, INT J IMMUNOPATH PH, V16, P49
[6]   Understanding Disease-Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window [J].
Coutant, D. E. ;
Kulanthaivel, P. ;
Turner, P. K. ;
Bell, R. L. ;
Baldwin, J. ;
Wijayawardana, S. R. ;
Pitou, C. ;
Hall, S. D. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 98 (01) :76-86
[7]  
Fleckenstein J, 2013, DTSCH Z AKUPUNKT, V56, P52, DOI 10.1016/j.dza.2013.03.024
[8]   Parecoxib, valdecoxib, and cardiovascular risk [J].
Furberg, CD ;
Psaty, BM ;
FitzGerald, GA .
CIRCULATION, 2005, 111 (03) :249-249
[9]   Pharmacokinetics of intravenous and intramuscular parecoxib in healthy Beagles [J].
Giorgi, M. ;
Saccomanni, G. ;
Del Carlo, S. ;
Manera, C. ;
Lavy, E. .
VETERINARY JOURNAL, 2012, 193 (01) :246-250
[10]   Nonsurgical oncological management of cancer pain [J].
Gough, Nicholas ;
Miah, Aisha B. ;
Linch, Mark .
CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2014, 8 (02) :102-111